A dilemma in advanced/metastatic NSCLC

Despite treatment advancements, personalized therapy is not an option for all patients.^1-3

Unfortunately, many patients do not harbor the actionable genomic alterations currently amenable to targeted therapy and few agents have been approved in the second-line setting.^1,2